About Molecular Templates
Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. MTEM’s pipeline of ETBs in development for other targets include CTLA-4, TIGIT, TROP2, and BCMA. MTEM has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. It also has an office in New York, NY.
|
|
|
51-200 employees
View all Molecular Templates employees
|
|
Biotechnology
|
|
9301 Amberglen Blvd, Suite 100, Austin, Texas 78729, US
|
|
2001
|
|
Biotechnology, Antibodies, Biologics, Etb, Immunooncology, Onoclogy
|
Molecular Templates Alternatives
Frequently Asked Questions about Molecular Templates
Eric Poma is the CEO of Molecular Templates. To contact Eric Poma email at [email protected] or [email protected].
Molecular Templates Staff Directory
Search Molecular Templates Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
